Investigational product~baseline: Vortioxetine 10mg (or placebo) qd + Acamprosate*~First 2 weeks: Vortioxetine 5-10mg (or placebo) qd+ Acamprosate*~Last 6 weeks: Vortioxetine 5-20mg (or placebo) qd + Acamprosate*~Acamprosate 666 mg bid for bodyweight < 60 kg; Acamprosate 666 mg tid for bodyweight ≥ 60 kg
This is a randomized, double-blinded, placebo-controlled, multicenter study. A total of 128 subjects will be randomly assigned to a test group or placebo group in a 1:1 ratio. Subjects will receive vortioxetine (or placebo) and acamprosate for 6 weeks according to the treatment group. Four visits will be made (weeks 0, 2, 4, 8), and on visit 2-4 (weeks 2, 4, 8) compliance, depression symptoms, and alcohol craving will be assessed.